Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Are Orphan Incentives Necessary For Development? Sponsors Aren't So Sure

Dec 03 2018

• By Derrick Gingery

Dollar sign made with drug pills

Related Content

US FDA's Orphan Drug Designation Reviews Often Don't Include Regulatory Histories, GAO Says

Dec 03 2018

Rare Disease Supporters Suggest Permanent PRV Program, Even If It May Concern FDA

Feb 28 2018

Drug Pricing Concerns May Hinder Rare Disease Lobbying Effort

Feb 28 2018

Not A Loophole? BIO Concerned About Limiting Orphan Designations For Pediatric Subsets of Common Diseases

Mar 05 2018

US FDA May Create Rare Disease Expert Pool For Advisory Committee Reviews

Oct 29 2018

Orphan Designations For Pediatric Subgroups Of Common Diseases To End

Dec 19 2017

Disease 'Subsetting' Not Driving Jump In Orphan Designations, US FDA Says

Nov 28 2016

Additional Topics

United States Rare Diseases Drug Review Regulation FDA BioPharmaceutical

More from Rare Diseases

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window